ABSTRACT
Even if firms operating in the pharmaceutical industry actively employ corporate divestitures to restructure their business portfolios, these operations often remain less acknowledged than acquisitions. However, firms can effectively enforce refocusing and downscoping strategies, reconfigure resources, and eliminate underperforming businesses by relying on divestitures. In this chapter, I map corporate divestiture as an additional facet of the merger and acquisition (M&A) landscape by discussing their motives, modes, and critical success factors to consider while implementing these operations.
